Skip to content

Study · Randomized controlled trial · 2000

2 results

Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.

Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer1 May 2000Cited by 90 (Europe PMC)

PMID10789958 (opens in a new tab)DOI10.1007/s005200050283 (opens in a new tab)PepBankPUB-10789958
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with malignant inoperable bowel obstruction, octreotide rapidly reduced daily vomiting episodes versus hyoscine butylbromide at the examined intervals.

    In plain wordsIn patients with malignant bowel obstruction, octreotide reduced daily vomiting episodes faster than hyoscine butylbromide.

    Peptide
    Octreotide
    Outcome
    DecreaseDaily vomiting episodes
    Study

    n: not reported in source

    Comparator
    Hyoscine butylbromide
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.3 mg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Octreotide treatment induced a significantly rapid reduction in the number of daily episodes of vomiting and intensity of nausea compared with HB treatment at the different time intervals examined.
    1 context sentence
    Summary · context
    Eighteen patients with inoperable bowel obstruction randomly received octreotide 0.3 mg daily (n = 9) or hyoscine butylbromide (HB) 60 mg daily (n = 9) s.c.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with malignant inoperable bowel obstruction, octreotide rapidly reduced nausea intensity versus hyoscine butylbromide at the examined intervals.

    In plain wordsIn patients with malignant bowel obstruction, octreotide reduced nausea faster than hyoscine butylbromide.

    Peptide
    Octreotide
    Outcome
    DecreaseNausea intensity
    Study

    n: not reported in source

    Comparator
    Hyoscine butylbromide
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.3 mg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Octreotide treatment induced a significantly rapid reduction in the number of daily episodes of vomiting and intensity of nausea compared with HB treatment at the different time intervals examined.
    1 context sentence
    Summary · context
    Eighteen patients with inoperable bowel obstruction randomly received octreotide 0.3 mg daily (n = 9) or hyoscine butylbromide (HB) 60 mg daily (n = 9) s.c.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.